Metronidazol Hikma

Metronidazole, the active ingredient in Metronidazol Hikma, is a nitroimidazole presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and related conditions in adults.

GNH USA supplies Metronidazol Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is employed to manage infections caused by anaerobic organisms and certain protozoa. - Anaerobic bacterial infections: eradicates susceptible anaerobes and resolves infection. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms. - Amebic liver abscess: kills Entamoeba histolytica in hepatic tissue. - Clostridioides difficile infection: reduces toxin‑producing bacteria and aids clinical recovery.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing pain. - Diarrhea: loose stools during treatment.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate care. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis or angioedema requiring emergency intervention.

Metronidazole requires careful use in specific clinical situations. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: use with caution; liver enzymes should be monitored. - Alcohol consumption: avoid during and 48 hours after therapy to prevent disulfiram‑like reaction. - Pregnancy: safety not established; weigh benefits against potential risks. - Concurrent anticoagulants: monitor for increased bleeding tendency. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metronidazole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: increased anticoagulant effect, risk of bleeding. - Lithium: heightened lithium toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma levels. - Cimetidine: may increase metronidazole concentrations. - Theophylline: may raise theophylline levels, risking toxicity.